What changed recently
Newly published and updated guidelines across every system, newest first. Each entry links to the official source.
141 older updates are outside this window. Show all time
- Reproductive & Women's HealthEU2026-07-07NICE guideline NG88 (March 2018) → NICE guideline NG88 (last updated July 2026)Uterine fibroids
The July 2026 update withdrew the recommendation on serum ferritin testing from the laboratory investigations section for women presenting with heavy menstrual bleeding. NG88 originally replaced the 2007 heavy menstrual bleeding guideline CG44.
- Gastrointestinal & HepatologyUS2026-07-012021 → 2026Diverticulitis
ACG replaced its 2021 diverticular disease guideline with a document focused on colonic diverticulitis, formalising selective rather than routine antibiotics for low-risk acute uncomplicated disease and listing the high-risk features (immunocompromise, frailty, unsafe outpatient care) that still warrant them. It also recommends against probiotics, mesalamine and rifaximin for recurrence prevention, drops nut/seed/popcorn avoidance, and limits post-recovery colonoscopy to complicated disease or patients with alarm features or overdue screening.
source ↗curation confidence 90% - Musculoskeletal & RheumatologyUS2026-06-242019 guideline → 2026 updateSpondyloarthritis
The 2026 revision of the 2019 adult guideline adds JAK inhibitors as a recommended option (a class absent from the previous version), keeps TNF and IL-17 inhibitors as the preferred first biologics, and advises against IL-23 inhibitors. It also broadens scope with new guidance on nociplastic pain, imaging strategy, bone health and comorbidities, and is accompanied by a first-ever companion guideline for juvenile axial spondyloarthritis.
- Musculoskeletal & RheumatologyEU2026-06-012022 update → 2025 updateRheumatoid arthritis
The task force consolidated the guidance from 11 recommendations down to 9 by merging and deleting items, while keeping methotrexate plus short-term glucocorticoids as the first step and adding a biologic DMARD after 3-6 months of inadequate response. Safety framing was sharpened, with JAK inhibitors requiring explicit assessment of cardiovascular and malignancy risk before use.
source ↗curation confidence 90% - Endocrine & MetabolicEU2026-05-132025 → 2026 updateObesity
Algorithm 2.0 refines the 2025 EASO framework using 62 randomised trials with evidence through 21 November 2025, sharpening the head-to-head comparisons of total body weight loss across available drugs. The liver domain was expanded beyond MASH resolution to include improvement in liver fibrosis as a treatment target.
- Renal & GenitourinaryUS2026-05-072021 guideline with 2023 amendment → 2026Benign prostatic hyperplasia
The AUA replaced its 2021 BPH/LUTS guideline and the targeted 2023 amendment with a full rebuild published in 2026, based on a fresh systematic literature review. The document was restructured into three parts covering presentation and evaluation, medical management, and procedural or surgical management.
source ↗curation confidence 90% - RespiratoryGLOBAL2026-05-012025 → 2026Asthma
The 2026 GINA report's headline addition is a set of four new flowcharts covering assessment, treatment and follow-up of acute asthma and exacerbations in adults, adolescents and children aged 6-11, in both primary and acute care settings. It also adds consensus guidance on which treatment step to start children aged 6-11 at, revised advice on biologics, oxygen saturation targets, SABA dosing and using ICS-formoterol instead of SABA for mild exacerbations, plus a stronger push to minimise oral corticosteroid exposure.
- Hematology & OncologyUS2026-04-162022 → 2022, amended 2026Prostate cancer
AUA amended the 2022 guideline after a literature review covering July 2021 to December 2024 (29 studies plus a set on artificial intelligence in disease management). The society describes the amendment as refining risk-based management, updating imaging and radiation therapy guidance, and strengthening the shared decision-making statements.
- Reproductive & Women's HealthEU2026-04-15NICE guideline NG23 (November 2024 update) → NICE guideline NG23 (updated November 2024; amended April 2026)Menopause
The April 2026 amendment reworked the advice on unscheduled vaginal bleeding while on systemic HRT, changing one recommendation and adding a new one so the guidance lines up with NICE's suspected cancer referral guidance. The preceding November 2024 update had added evidence-based recommendations on cognitive behavioural therapy for menopausal symptoms, on genitourinary symptoms, and on the health outcomes associated with HRT.
- Hematology & OncologyEU2026-04-142023 → 2026Colorectal cancer
ESMO replaced its 2023 metastatic colorectal cancer guideline with the 2026 edition (Cremolini et al., Ann Oncol 37(6):759-776); the 2023 document is now marked superseded in this atlas.
- Immunology & AllergyUS2026-04-012015 → 2025 practice parameterPrimary immunodeficiency
The 2025 parameter abandons the previous edition's structure of working through individual genetic entities and instead organises recommendations into a diagnosis part and a management part. Diagnosis now covers newborn screening for severe combined immunodeficiency, genetic testing and comorbidity surveillance, while management addresses immunoglobulin replacement, antibiotic prophylaxis, haematopoietic stem cell transplantation, precision medicine and quality-of-life assessment.
source ↗curation confidence 90% - Infectious DiseaseGLOBAL2026-04-012021 → 2026Sepsis & septic shock
The 2026 edition expands to 129 statements, 46 of them on questions the 2021 guidelines never addressed, including a conditional recommendation for point-of-care ultrasound to guide resuscitation and new guidance on active fluid removal once initial resuscitation is complete. Of the 38 questions carried over from 2021, only three recommendations actually reversed direction.
- Neurology & Special SensesUS2026-01-262019 Update → 2026Ischemic stroke
The 2026 guideline supersedes the 2018 guideline and its 2019 focused update, placing tenecteplase 0.25 mg/kg on equal footing with alteplase inside the 4.5-hour window, allowing imaging-selected thrombolysis out to roughly 9 hours, widening thrombectomy eligibility to include basilar occlusions and large ischaemic cores, endorsing mobile stroke units and refined EMS triage, and adding the first AHA/ASA recommendations for paediatric acute ischaemic stroke.
- Endocrine & MetabolicUS2026-01-012025 → 2026Diabetes complications
The 2026 edition added a new pathophysiology introduction drawing on 40-year DCCT/EDIC follow-up, discussed the eye effects of GLP-1 receptor agonists including NAION and retinopathy progression, added the Ipswich touch test to neuropathy assessment, and revised Rec 12.22 to stress combination therapy for neuropathic pain. Foot care sections now cover home foot-temperature monitoring, expanded WIfI staging, and emerging evidence that GLP-1 RAs may cut lower-extremity amputations.
- Endocrine & MetabolicUS2026-01-012025 → 2026Type 2 diabetes
The 2026 edition added a recommendation to use a dual GIP/GLP-1 receptor agonist in type 2 diabetes with symptomatic heart failure with preserved ejection fraction, and reworked the MASLD/MASH guidance so a GLP-1 RA with proven hepatic benefit is preferred, with pioglitazone or a dual GIP/GLP-1 RA as alternatives. Guidance on continuing GLP-1-based therapy in advanced chronic kidney disease was also expanded.
- Endocrine & MetabolicUS2026-01-012025 → 2026Type 1 diabetes
For insulin-treated diabetes the 2026 edition broadened continuous glucose monitoring to be offered at diagnosis and at any later point (Rec 9.25), and strengthened the recommendation that automated insulin delivery systems be offered to eligible adults. A new recommendation also addresses screening for insulin need and ketoacidosis risk in immune checkpoint inhibitor-associated diabetes.
- DermatologyEU2026-01-012018 EDF atopic eczema guideline → Living guideline, January 2026 updateAtopic dermatitis
The January 2026 update to the living EuroGuiDerm atopic eczema guideline re-voted the systemic treatment chapters and redrew the treatment algorithms for adults and for children and adolescents. Azathioprine and alitretinoin recommendations were withdrawn, mycophenolate and omalizumab were moved to past therapies, and new guidance was added on vaccination, switching between drugs, dose interval adjustment, and pregnancy and breastfeeding.
source ↗curation confidence 90% - DermatologyEU2026-01-012016 European evidence-based (S3) guideline → Update 2025Acne
The EuroGuiDerm update revises the 2016 European S3 acne guideline around three priority questions: when to choose isotretinoin over systemic antibiotics, how long antibiotics should run and when to use hormonal therapy or spironolactone, and how to position the newer topicals trifarotene and clascoterone. It also revises advice on benzoyl peroxide safety, choice of systemic antibiotic, treatment in pregnancy and isotretinoin dosing, leaving the rest of the 2016 text in place.
source ↗curation confidence 90% - Renal & GenitourinaryEU2026-01-012025 → 2026Urinary tract infection
The 2026 EAU urological infections guideline is a limited update of the 2025 edition adding 36 studies across two sections. It revises the diagnostic and antimicrobial treatment recommendations for cystitis, updates antibiotic dosages throughout, strengthens periprocedural antibiotic prophylaxis guidance for prostate biopsy, and adds a new section on the diagnosis and treatment of fungal urinary tract infections.
- Renal & GenitourinaryEU2026-01-012025 → 2026Nephrolithiasis
The 2026 EAU urolithiasis guideline is a full update of the 2025 edition incorporating 126 newly identified studies, with revised recommendations on renal colic management, medical expulsive therapy, antibiotic prophylaxis for shock wave lithotripsy, retrograde and antegrade ureteroscopy, percutaneous nephrolithotomy, management of antithrombotic therapy around stone treatment, and radiation protection in endourology.
- Renal & GenitourinaryEU2026-01-012025 → 2026Benign prostatic hyperplasia
The 2026 EAU male LUTS guideline is a full revision of the 2025 edition: it adds a new section on prostate cancer within the diagnostic chapter, changes the strength rating for beta-3 agonists in conservative treatment, expands the surgical chapter with two new subsections emphasising alternative enucleation and ablative techniques, and adds guidance on male urinary incontinence, detrusor underactivity and voiding dysfunction in younger men.
- Dental & Oral HealthUS2026-01-012017 guideline → Living guideline, 2026 updateOral cancer
The 2026 living guideline updates the ADA's 2017 statement on potentially malignant oral disorders and now conditionally recommends against vital staining adjuncts such as toluidine blue for deciding on biopsy or referral, warning they can prompt unnecessary procedures or delay diagnosis. Conventional visual and tactile examination plus scalpel or punch biopsy with histopathology is reaffirmed as the standard pathway.
- Hematology & OncologyEU2026-01-012025 → 2026 editionProstate cancer
The EAU panel describes the 2026 text as a limited update of the 2025 publication, with revised evidence summaries and recommendations for MRI in biopsy indication and strategy, for staging, and for active surveillance strategy, plus an adapted EAU risk-group table for localised and locally advanced disease.
- Hematology & OncologyUS2026-01-012026.1.0 → 2026.1.1Multiple myeloma
This living-guideline version bump revisits the evidence base from a February 2026 literature search and issues updated recommendations covering the teclistamab plus daratumumab combination; the preceding 2026.1.0 release had itself replaced the 2019 guideline by adding first-ever guidance on smoldering myeloma and incorporating CAR T-cell, bispecific antibody and antibody-drug conjugate options.
source ↗curation confidence 90% - Endocrine & MetabolicUS2025-12-092016 → 2025 UpdateObesity
The 2025 update to AACE's 2016 obesity guidance moved diagnosis away from BMI alone toward adiposity-based criteria and complication-driven staging, and reframed treatment success around metabolic health and complication resolution rather than weight loss percentage. It also added explicit hierarchies of preferred medications matched to each obesity-related complication, reflecting the arrival of highly effective incretin-based agents.
source ↗curation confidence 90% - Immunology & AllergyEU2025-12-012016 revision → ARIA-EAACI 2024-2025 revision, Part IAllergic rhinitis
This ARIA revision rebuilds the intranasal treatment recommendations around eleven prioritised questions using the GRADE evidence-to-decision framework, drawing on mHealth and pharmacovigilance data and an expert cost survey alongside systematic reviews. It now suggests a fixed combination of intranasal antihistamine plus intranasal corticosteroid ahead of either agent alone, and intranasal corticosteroid ahead of intranasal antihistamine when a single agent is used.
source ↗curation confidence 80% - Hematology & OncologyUS2025-12-012020 → 2025 updateLeukemia
The 2025 ASH panel retired the 2020 guideline's split between "intensive" and "non-intensive" therapy, framing recommendations instead around candidacy for antileukaemic therapy, and it now positions venetoclax-based combinations alongside conventional induction and post-remission therapy for older adults with newly diagnosed AML.
source ↗curation confidence 90% - Renal & GenitourinaryUS2025-11-202016 → 2025Nephrolithiasis
The AUA replaced its 2016 surgical stone guideline with a new edition released in November 2025, developed from a GRADE-based review of literature published between 2000 and 2025. It is issued as a three-part series spanning evaluation, treatment and future directions, and covers shock wave lithotripsy, ureteroscopy and both standard and mini percutaneous nephrolithotomy.
source ↗curation confidence 90% - RespiratoryGLOBAL2025-11-102025 → 2026COPD
The 2026 GOLD report widens the 'exacerbator' label so a single moderate or severe exacerbation in the past year now counts (previously two or more were needed), reframes the ABE assessment around disease activity, stability and control, revises the exacerbation-severity classification, and positions high-flow nasal therapy as a first-line respiratory support option in exacerbations. A new chapter on emerging technology and artificial intelligence in COPD was also added.
- Gastrointestinal & HepatologyUS2025-11-012018 → 2025 updateHepatitis B
The 2025 AASLD/IDSA guideline tackles six GRADE-based questions the 2018 guidance left unresolved, including whether to treat HBsAg-positive people in the immune-tolerant and indeterminate phases, when to withdraw antiviral therapy, and HCC surveillance in HBV coinfection and after HBsAg loss. Recommendations from 2018 that were not revisited remain in force, and an integrated algorithm combines old and new guidance.
source ↗curation confidence 90% - Emergency & Critical CareUS2025-10-222020 → 2025Cardiac arrest & ACLS
The 2025 edition replaces the four separate 2020 Chains of Survival with a single unified six-link chain spanning adult, paediatric and in-hospital arrest, and adds first-time guidance for choking in responsive adults using alternating back blows and abdominal thrusts. It also advises against routine mechanical CPR devices, reserving them for situations where manual compressions are unsafe or impractical, and extends delayed cord clamping in newborns to at least 60 seconds.
- Infectious DiseaseUS2025-10-142023 guideline → Living guideline, updated October 2025COVID-19
The October 2025 antiviral update reframed treatment decisions around preventing hospitalisation rather than death, given higher population immunity. It keeps a strong recommendation for nirmatrelvir/ritonavir in adults at high risk of progression but now suggests against routine antiviral treatment in mild to moderate COVID-19 without risk factors.
source ↗curation confidence 80% - Infectious DiseaseEU2025-10-0112.1 → 13.0HIV
Version 13.0 restructured the guidelines into two parts, added a new consolidated Substance Use section covering alcohol, opioid use and chemsex, and extensively rewrote the obesity guidance to cover pharmacotherapy and bariatric surgery. Recommended first-line ART regimens for treatment-naive adults were left unchanged from v12.1, and the lipodystrophy section was retired.
- Hematology & OncologyUS2025-10-012.2025 → 3.2025Lymphoma
NCCN's published Insights article for this version bump describes the panel's discussion of newly incorporated data in three areas: CD3xCD20 bispecific antibodies and CD19-directed antibodies/antibody-drug conjugates in relapsed or refractory follicular lymphoma, BTK inhibitor-based regimens in TP53-mutated classical mantle cell lymphoma, and bispecific antibodies added to chemoimmunotherapy in relapsed or refractory DLBCL.
source ↗curation confidence 90% - Infectious DiseaseUS2025-09-25September 12, 2024 update → Living guideline, updated September 2025HIV
The September 2025 revision added a dedicated chapter on cardiovascular and metabolic complications as people with HIV approach normal life expectancy, and retired the standalone statin primary-prevention section in favour of the ACC/AHA multisociety dyslipidaemia guidance. It also revised laboratory monitoring intervals, added subsections on starting ART in early infection and in hospitalised patients, and expanded cost guidance around long-acting injectables.
source ↗curation confidence 90% - Neurology & Special SensesEU2025-09-085th Edition → 6th EditionGlaucoma
The 6th edition refreshes the evidence-based chapter with a new set of clinical questions and GRADE-style answers, and substantially rewrites the 'what matters to patients' material using direct input from patient advisors in the EGS Patient Involvement Project, including eight practical communication tips for clinicians.
source ↗curation confidence 90% - Renal & GenitourinaryUS2025-09-042019 guideline (reviewed and reaffirmed 2022) → 2025 amendmentUrinary tract infection
The AUA, CUA and SUFU amended their 2019 recurrent uncomplicated UTI guideline in September 2025, after the document had been reviewed and its validity confirmed in 2022. The amended version carries 20 recommendations, with revisions concentrated in the evaluation section, including how the diagnosis of recurrent UTI is established and the strength assigned to patient-initiated self-start treatment.
source ↗curation confidence 90% - CardiovascularEU2025-08-292021 → 2025Mitral regurgitation
The 2025 guideline replaces the 2021 edition and moves mitral intervention earlier: repair surgery becomes a Class I option in selected asymptomatic primary mitral regurgitation, and transcatheter edge-to-edge repair is upgraded to Class I in symptomatic severe ventricular secondary regurgitation with reduced ejection fraction, with new recommendations added for atrial secondary regurgitation.
source ↗curation confidence 90% - CardiovascularEU2025-08-292021 → 2025Aortic stenosis
Updating the 2021 ESC/EACTS guideline, the 2025 version lowers the age cut-off favouring transcatheter aortic valve implantation in tricuspid aortic stenosis from 75 to 70 years, tightens the echocardiographic criteria for grading stenosis severity, and lowers thresholds for intervening earlier.
source ↗curation confidence 90% - Hematology & OncologyEU2025-07-072021 → 2025Multiple myeloma
The EHA-EMN 2025 guideline replaced the 2021 EHA-ESMO guideline, adopting the R2-ISS staging system and adding minimal residual disease, circulating plasma cells and mass-spectrometry monoclonal protein as prognostic factors, alongside 14 novel EMA/FDA-approved regimens.
- RespiratoryUS2025-07-012013 → 2025Lung cancer
Replacing the 2013 CHEST guideline on stage I and II NSCLC, the 2025 version backs minimally invasive resection over open thoracotomy on the strength of a new meta-analysis showing better overall survival, and accepts sublobar resection as equivalent to lobectomy for peripheral tumours of 2 cm or less. It also recommends adjuvant chemotherapy after complete resection of stage II disease and adjuvant targeted therapy for resected stage IB tumours carrying EGFR exon 19 deletion or L858R mutations.
source ↗curation confidence 90% - RespiratoryUS2025-07-012019 → 2025Community-acquired pneumonia
The 2025 ATS guideline reverses the 2019 position that every adult with CAP and a positive influenza test should receive antibiotics, now suggesting antibiotics be withheld in otherwise healthy patients with a positive viral test. It also accepts lung ultrasound as an alternative to chest radiography where the preferred imaging is unavailable and staff are trained, supports stopping empiric antibiotics at 48-72 hours in patients with low procalcitonin and early clinical stability, and splits the steroid advice by severity: against systemic corticosteroids in non-severe inpatient CAP, in favour of them in severe CAP.
source ↗curation confidence 90% - CardiovascularEU2025-06-152019 → 2025 Focused UpdateDyslipidemia
2025 focused update of the 2019 ESC/EAS guideline, incorporating newer lipid-lowering trial evidence while retaining risk-based LDL-C goals.
- CardiovascularUS2025-06-152017 → 2025Hypertension
First full US revision since 2017: adopts the PREVENT equations for risk estimation (replacing the Pooled Cohort Equations) and reaffirms a <130/80 mm Hg treatment goal.
- Infectious DiseaseGLOBAL2025-06-01Version 7 → Version 8 (June 2025)COVID-19
Version 8 added two new antibiotic-stewardship recommendations drawn from a meta-analysis of antibiotic use in COVID-19: withhold empirical antibiotics in non-severe COVID-19 when bacterial co-infection is clinically unlikely (strong), and likewise suggest withholding them in severe COVID-19 with low suspicion of co-infection (conditional).
source ↗curation confidence 90% - Gastrointestinal & HepatologyUS2025-06-012018 → 2025Crohn disease
The 2025 ACG guideline moves away from the 2018 step-up model, suggesting against requiring failure of conventional therapy before starting advanced therapy and endorsing early treat-to-target management with therapy chosen by phenotype and prior exposure. It also recommends combination infliximab plus a thiopurine over either agent alone in biologic- and immunomodulator-naive patients.
source ↗curation confidence 90% - Gastrointestinal & HepatologyUS2025-06-012019 → 2025 updateUlcerative colitis
This update revises the 2019 ACG ulcerative colitis guideline with five years of new trial evidence, expanding and repositioning advanced therapies for moderate-to-severe disease. Etrasimod, an S1P receptor modulator, is newly recommended for both induction and maintenance of remission.
source ↗curation confidence 90% - Neurology & Special SensesEU2025-05-222014 → 2025Intracerebral hemorrhage
This GRADE-based joint ESO/EANS document replaces the 2014 ESO ICH guideline, answering 37 PICO questions with evidence accumulated from a decade of randomised trials. It supports early intensive blood-pressure lowering mainly for reducing haematoma expansion rather than for proven functional benefit, weighs anticoagulation reversal explicitly against thromboembolic harm, treats minimally invasive evacuation alongside open craniotomy as options for supratentorial haemorrhage, and advises against anti-inflammatory drugs outside trials.
source ↗curation confidence 90% - Gastrointestinal & HepatologyEU2025-05-102017 → 2025Hepatitis B
EASL's 2025 hepatitis B guideline shifts from indefinite viral suppression toward personalised, finite therapy with functional cure (sustained HBsAg loss) as the goal. Newer biomarkers including quantitative HBsAg, HBcrAg and HBV RNA are built into disease staging, treatment selection and decisions about safely stopping antivirals.
source ↗curation confidence 90% - Neurology & Special SensesGLOBAL2025-04-232017 → 2025Epilepsy
The 2025 ILAE position paper revises the 2017 operational seizure classification, keeping the four main classes but separating diagnostic classifiers from descriptors, expanding the scheme to 21 seizure types, classifying focal and unknown-onset seizures by whether consciousness is impaired or preserved, and adding negative myoclonus as a recognised generalised seizure type.
source ↗curation confidence 90% - RespiratoryGLOBAL2025-04-152022 → 2025Tuberculosis
The 2025 edition supersedes the December 2022 update that introduced BPaLM, adding a recommendation for a new all-oral six-month regimen (bedaquiline, delamanid, linezolid, levofloxacin and clofazimine) for multidrug- or rifampicin-resistant TB including pre-XDR disease, plus modified nine-month regimens where fluoroquinolone resistance has been excluded. The changes rest on evidence from the BEAT-Tuberculosis and endTB trials.
- Renal & GenitourinaryGLOBAL2025-04-012021 (Chapter 4 of the KDIGO Glomerular Diseases guideline) → 2025Nephrotic syndrome
This guideline replaces Chapter 4 of the 2021 KDIGO glomerular diseases guideline, with most changes affecting treatment. It tightened the definition of infrequently relapsing disease from fewer than four to fewer than three relapses in a 12-month period and aligned its clinical definitions with the International Pediatric Nephrology Association guideline.
source ↗curation confidence 90% - CardiovascularUS2025-02-272013 STEMI / 2014 NSTEMI guidelines → 2025Post-MI care
The 2025 guideline consolidates the 2013 STEMI, 2014 NSTEMI and 2015 primary-PCI focused update into one document covering the whole ACS spectrum, and refreshes post-infarction antithrombotic and revascularisation guidance, including intracoronary imaging to guide PCI and revised anticoagulant choices.
- CardiovascularUS2025-02-272013 STEMI / 2014 NSTEMI guidelines → 2025Acute coronary syndrome
The 2025 guideline merges the separate 2013 STEMI and 2014 NSTEMI documents (plus the 2015 primary-PCI focused update) into a single guideline spanning unstable angina, NSTE-ACS and STEMI. New positions include a recommendation to use intracoronary imaging to guide PCI, a weak (Class 2b) option for bivalirudin in NSTE-ACS to limit bleeding, and advice against fondaparinux as the sole anticoagulant during PCI.
- DermatologyEU2025-02-01September 2023 version → February 2025 partial updatePsoriasis
The February 2025 partial update to the living EuroGuiDerm psoriasis guideline changed recommendations in the viral hepatitis chapter and rewrote the pregnancy and wish-for-child chapter around new data, adding pregnancy content to the main recommendations and decision grid. It also revised the laboratory monitoring advice for deucravacitinib.
- PediatricsEU2025-01-14CG189 (2014) → NG246Childhood obesity
NG246 consolidates CG189 and several other NICE obesity products into one guideline covering children as well as adults, and reframes overweight and obesity as chronic conditions needing continuing support rather than episodic weight-loss episodes. It drops the tiered weight-management service model in favour of a range of services, and adds recommendations on non-judgemental language and on the wider determinants of obesity.
- Psychiatry & BehavioralUS2025-01-012017 → 2025Post-traumatic stress disorder
The 2025 APA guideline replaces the 2017 edition, which rested on a single systematic review, and instead draws on 15 systematic reviews while weighing outcomes beyond PTSD symptom scores. It gives strong recommendations to cognitive processing therapy, prolonged exposure and trauma-focused CBT as first-line treatment for adults, with EMDR carried as a conditional recommendation.
source ↗curation confidence 90% - Emergency & Critical CareUS2025-01-0110th edition → 11th editionTrauma initial evaluation
ATLS 11 shifts the primary survey to an xABCDE sequence that puts control of exsanguinating haemorrhage ahead of the airway, and moves to balanced resuscitation with early 1:1:1 blood component therapy rather than crystalloid-led volume replacement. Glasgow Coma Scale assessment changes from the 10th edition's single total score to combined component and trend scoring, with new emphasis on recognising herniation and preventing secondary brain injury from the primary survey onward.
source ↗curation confidence 90% - Emergency & Critical CareEU2025-01-012021 → 2025Cardiac arrest & ACLS
The 2025 ERC guidelines supersede the 2021 edition, folding CPR-quality and technology guidance into the individual chapters instead of treating it separately and strengthening the message to call emergency services for any unresponsive person before assessing breathing. Advanced life support adds emphasis on effective ventilation and correct pad placement, positions extracorporeal CPR as an option in specialist centres when conventional CPR fails, and addresses sedation for CPR-induced consciousness.
source ↗curation confidence 90% - DermatologyEU2025-01-01Update 2022 → Update 2024, Part 1 (Diagnostics)Melanoma
The 2024 diagnostics update to the European melanoma guideline lowered the threshold for whole-body staging: CT or PET-CT combined with brain MRI is now advised from stage IIB/C rather than from stage IIC as in the 2022 version. It also sets out when BRAF V600 mutation testing is indicated and endorses sequential digital dermoscopy, whole-body photography and reflectance confocal microscopy in selected high-risk patients.
source ↗curation confidence 90% - DermatologyUS2025-01-012023-2024 AAD atopic dermatitis guidelines → Focused update (2025)Atopic dermatitis
The 2025 focused update adds four new recommendations to the 2023-2024 AAD atopic dermatitis guidelines, covering therapies approved after those documents were written: the topicals tapinarof and roflumilast and the biologics lebrikizumab and nemolizumab. Tapinarof 1% cream received a strong recommendation for adults.
source ↗curation confidence 90% - Neurology & Special SensesUS2025-01-012020 (published 2021) → 2025Glaucoma
The 2025 POAG PPP strengthens the endorsement of selective laser trabeculoplasty as an initial rather than merely adjunctive therapy, drawing on the LiGHT trial's six-year extension data, and newly incorporates evidence on sustained-release drug delivery and minimally invasive glaucoma surgery, macular and ganglion-cell-layer imaging, corneal hysteresis as a risk metric, and more intensive monitoring for rapid progressors.
source ↗curation confidence 90% - Preventive Medicine & Primary CareEU2025-01-012019 → 2025 focused updateStatins for primary prevention
The 2025 focused update leaves the 2019 LDL-cholesterol targets intact but changes how they are reached, pushing earlier and more aggressive combination therapy (high-intensity statin plus ezetimibe, including during the index acute coronary syndrome admission) and adding recommendations covering bempedoic acid, inclisiran and evinacumab. Risk stratification is refined with SCORE2/SCORE2-OP, lipoprotein(a) and coronary artery calcium scoring.
source ↗curation confidence 90% - Reproductive & Women's HealthEU2024-12-27NICE guideline CG62 (March 2008) → NICE guideline NG201 (last updated December 2024)Prenatal care
NG201 updated and replaced the 2008 antenatal care guideline CG62 when it was published in August 2021, and also superseded evidence summary ES20. Revisions since then have been maintenance changes rather than new clinical recommendations, the December 2024 one adding a cross-reference to NICE's guideline on end of life care for adults.
- PediatricsEU2024-11-27NG80 (2017) and BTS/SIGN 158 (2019) → NG245Pediatric asthma
The first joint BTS/NICE/SIGN guideline replaced NICE NG80 and parts of BTS/SIGN 158, ending short-acting beta-agonist monotherapy: every patient with asthma should receive inhaled corticosteroid-containing treatment. For those aged 12 and over the preferred pathway is now anti-inflammatory reliever or MART with combination ICS-formoterol, and the diagnostic pathway was reworked around objective testing.
- Immunology & AllergyEU2024-10-302014 → 2025Food allergy
This revision of the 2014 EAACI food allergy management guideline (which also absorbs the 2018 food immunotherapy guideline) shifts the emphasis from avoidance and watchful waiting to active management, recommending oral, sublingual and epicutaneous immunotherapy for peanut allergy plus oral immunotherapy for egg and milk, and incorporating omalizumab following its US approval for IgE-mediated food allergy from age one. It adds a conditional recommendation for psychological support in patients with significant anxiety and a strong recommendation to keep eating tolerated foods to protect nutrition.
- Gastrointestinal & HepatologyEU2024-10-012020 → 2024Crohn disease
The 2024 ECCO therapeutics update adds strong recommendations for the newer agents risankizumab (maintenance) and upadacitinib (induction and maintenance) in moderate-to-severe Crohn's disease, broadening options beyond anti-TNF and older biologics. It also restructures the guidance into actionable practice points alongside the GRADE recommendations carried over from 2020.
source ↗curation confidence 90% - Infectious DiseaseGLOBAL2024-09-132022 → 2024Influenza
The 2024 WHO update extended scope from severe influenza to non-severe disease and added recommendations on baloxavir marboxil, favipiravir and umifenovir. It advises against oseltamivir in non-severe influenza, conditionally supports early baloxavir only for non-severe patients at high risk of progression, and keeps oseltamivir as a conditional option for severe influenza.
source ↗curation confidence 90%